MiNK Therapeutics Q2 2025 net loss $4.2M; extends runway with $13M raise; GvHD grants awarded

MiNK Therapeutics, Inc.

2025-Q2 EPS reported -$1.76

Cash at Q2 end $1.6M; raised $13M post-quarter; runway extended beyond mid-2026.
Net loss Q2 2025 $4.2M ($1.06/shr) vs $2.7M ($0.73/shr) in Q2 2024.
Durable complete remission in metastatic testicular cancer published; patient disease-free >2 years.
DOD STTR grant and new clinical grant awarded for iNKT cell therapy in GvHD; trial target 2H2025.
Phase 2 gastric cancer trial of agenT-797 expects additional readouts in 2025.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.